PRP nebulizer for lung diseases - an innovative treatment method

Blood plasma therapy can be helpful in treating many types of lung disease and is being studied as a potential treatment for COVID19. Platelet rich plasma (PRP) has been shown to help patients with conditions such as pulmonary fibrosis and blood antibodies. of COVID19 survivors may also help others recover.

Platelet Rich Plasma (PRP) is based on the concentration of platelets present in the blood. Platelets are small nucleated cells derived from megakaryocytes and are biosynthesized in both the bone marrow and lungs. Its action is based not only on the regulation of thrombosis, but also on the biological activity of the complex set of chemokines, cytokines and growth factors released by platelet granules, which can trigger biological processes of proliferative, antifibrotic and anti-inflammatory nature; therefore, they are classically considered to be mainly responsible for hemostasis, wound healing, anti-inflammatory activity and tissue repair. However, recent research has also shown that platelets are associated with antiviral activities and lung biology and physiology. Although platelets are important in activating antiviral defenses, it has been shown that viruses can also affect platelets by converting viral RNA into proteins, thereby converting healthy platelets into harmful ones.

Considering the aforementioned pathophysiology caused by covid19 and other respiratory tract infections, PRP-based therapies could counteract the loss of healthy platelets by locally managing healthy platelet content, thus recovering and strengthening its biological effects, promoting regeneration of damaged lung tissue and reducing fibrosis.

PRP is known to contain several growth factors that reduce inflammation, decrease the production of harmful molecules such as cytokines (as in cytokine storm in Covid-19), break down scar tissue, etc. PRP also acts as a nutrient for the cells so that they can perform their functions better.